3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
104
Neoplasms
13
Neoplasm Metastasis
8
Sarcoma
6
Pancreatic Neoplasms
6
Ovarian Neoplasms
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Melanoma
5
Leukemia, Myeloid, Acute
5
Colorectal Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Squamous Cell Carcinoma of Head and Neck
4
Prostatic Neoplasms
4
Lung Neoplasms
4
Liposarcoma
4
Multiple Myeloma
3
Head and Neck Neoplasms
3
Glioblastoma
3
Endometrial Neoplasms
3
Colonic Neoplasms
3
Breast Diseases
3
Brain Neoplasms
3
Triple Negative Breast Neoplasms
2
Recurrence
2
Neoplasm, Residual
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Mantle-Cell
2
Inflammation
2
Estrogen Receptor-positive Breast Cancer
2
Esophageal Squamous Cell Carcinoma
2
Interventions
palbociclib
1
aumolertinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
EGFR Tyrosine Kinase Inhibitors Plus Cyclin-dependent Kinase 4/6 Inhibitor
×
palbociclib
×
Clear all
NCT06947811
2025-06-04
APEAK
Sun Yat-sen University
Phase 1/2
Recruiting
71 enrolled